Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 2.37% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Commodity Chemicals
INR 66 Cr (Micro Cap)
NA (Loss Making)
34
0.00%
0.49
-7.84%
4.36
Total Returns (Price + Dividend) 
Shreyas Interm. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Shreyas Intermediates: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals
Shreyas Intermediates, a player in the commodity chemicals sector, has experienced a revision in its market assessment driven primarily by changes in technical indicators, alongside a complex financial backdrop. This article examines the recent shifts across quality, valuation, financial trends, and technical parameters that have influenced the company's current evaluation.
Read More
Shreyas Intermediates Forms Golden Cross, Indicating Potential Bullish Breakout
Shreyas Intermediates, a player in the Commodity Chemicals sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average crosses above the 200-day moving average. This development is widely regarded as a bullish signal, suggesting a possible shift in long-term momentum and a potential trend reversal for the stock.
Read More
Shreyas Intermediates: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals
Shreyas Intermediates, a player in the Commodity Chemicals sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing amid fluctuating market conditions.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2025 | Source : BSENewspaper Cuttings in connection with the Un-audited Financial Results for the quarter and half year ended 30.09.2025 in terms of Regulation 30 & 47 of SEBI (LODR) Regulatins 2015.
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14/11/2025 And Submission Of Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025
14-Nov-2025 | Source : BSEThe Board of Directors in its meeting held on Friday 14th November 2025 at 4:00 p.m. have considered and approved the following: 1. Un-Audited Financial Results for the quarter and half year ended on 30th September 2025 along with Limited Review Report thereon. Kindly take the above in your records and acknowledge the receipt of the same. The Board Meeting concluded at 5:00 p.m.
Regulation 33 For The Quarter And Half Year Ended 30Th September 2025
14-Nov-2025 | Source : BSEPursuant to Regulation 33 of the SEBI (LODR) REgulation 2015 the board of Directors in their Meeting held on 14.11.2025 have approved the unaudited financial results of the company for the Quarter ended 30.09.2025 alongwith the limited review report thereon.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
10.028
Held by 3 Schemes (0.0%)
Held by 1 FIIs (8.42%)
Kesar Petroproducts Limited' (27.59%)
Krish Pharma Speciality Private Limited (24.7%)
7.76%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 64.08% vs 0.00% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 29.41% vs -13.33% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 36.26% vs -8.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 11.81% vs -0.70% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -0.63% vs -0.64% in Mar 2024






